Investors Facing Losses in ADMA Biologics Are Called to Act Against Class Action Lawsuit

Investor Action Alert: Class Action Lawsuit Against ADMA Biologics

Investors who have experienced losses due to their investments in ADMA Biologics, Inc. (NASDAQ: ADMA) are being urged to take action. The Pomerantz Law Firm has recently announced the filing of a class action lawsuit, highlighting the significant allegations of securities fraud and unlawful business practices within the company. Individuals who purchased ADMA securities within the specified Class Period have until August 10, 2026, to join the class action and seek justice.

The current class action lawsuit stems from serious allegations made by Culper Research on March 24, 2026. They claimed that the reported revenue growth of ADMA was artificially inflated through questionable practices, including channel stuffing, which is when a company sends more products to retailers than they can sell, in order to inflate revenue figures. Culper's short report estimates that, absent these practices, ADMA's revenues actually declined by 3% in 2025, steeply contrasting the reported increase of 20%.

Following the publication of this report, ADMA's stock saw a significant drop, falling by $2.26 per share or 16.63%, closing at $11.33. This alarming shift in stock value drew further scrutiny, leading to a downgrade from Cantor Fitzgerald on March 26, 2026, due to the company’s insufficient response to the report. This downgrade triggered another decline in stock price, falling by $1.34 per share, or 13.91%, with shares closing at $8.29 on that day.

In light of these developments, investors are strongly advised to seek further information and consider initiating their participation in the class action. They can contact Danielle Peyton at Pomerantz LLP via email at [email protected] or call 646-581-9980 for further assistance. Investors should include their mailing address, telephone number, and details of the shares purchased for an expedited response.

Founded by Abraham L. Pomerantz, the Pomerantz Law Firm has a long-standing reputation in the field of corporate and securities litigation. With offices located in key global cities like New York, Chicago, and London, the firm has established itself as a leader in securing justice for victims of corporate malpractice. Their historical successes include numerous multimillion-dollar recoveries for class members, showcasing their commitment to fighting against wrongdoing in the corporate sector.

As the class action lawsuit progresses, further information can be accessed through the Pomerantz Law Firm's official site, where a complete copy of the complaint is available for review. Investors remain encouraged to act swiftly not only to protect their financial interests but also to hold accountable those responsible for any breaches of trust or misconduct in a company they invested in.

Staying informed and proactive in the face of financial loss is paramount for any investor. The Pomerantz Law Firm continues to advocate for shareholder rights, embodying the legacy of its founder who was dedicated to addressing injustice in the marketplace. Investors have a choice—to be heard and to make a stand against corporate deceit—by joining the ongoing class action lawsuit against ADMA Biologics. Time is of the essence; for those affected, now is the opportunity to act.